Search Results | Blood | American Society of Hematology

1-20 of 304

2 3 4 5

Sort by

Sort Order Select

Journal Articles

Incidence and Cost of Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome with and without Multi-Organ Dysfunction: Analysis of the Premier Healthcare Database

Christopher C. Dvorak, MD, Zhun Cao, PhD, Kwanza Price, MPH, JeanPierre Coaquira, Craig Lipkin, Scott Robinson, Partow Kebriaei, MD

Blood (2019) 134 (Supplement_1): 4706.

DOI: https://doi.org/10.1182/blood-2019-123499

Published: 2019

Journal Articles

Comparable Outcomes between Unrelated Donor (8/8 or 7/8 matched) and Haploidentical Donor for Allogeneic Stem Cell Transplantation in Adult Patients with Severe Aplastic Anemia

Jee Yon Shin, Sung-Soo Park, Gi June Min, MD, Silvia Park, Sung-Eun Lee, MD, Jae-Ho Yoon, MD PhD, Seung-Hwan Shin, MD PhD, Sung-Eun Lee, MD, Ki-Seong Eom, MD PhD, Yoo-Jin Kim, MD PhD, Seok Lee, MD PhD, Chang-Ki Min, MD PhD, Hee-Je Kim, MD PhD, Seok-Goo Cho, MD PhD, Jong-Wook Lee, MD

Blood (2019) 134 (Supplement_1): 4619.

DOI: https://doi.org/10.1182/blood-2019-130419

Published: 2019

Journal Articles

Efficacy and Safety Outcomes in the Phase 3 INO-Vate Trial By Baseline CD22 Positivity Assessed By Local Laboratories

Hagop M. Kantarjian, MD, Wendy Stock, MD, Ryan D. Cassaday, MD, Daniel J. DeAngelo, MD PhD, Elias Jabbour, MD, Susan M. O'Brien, MD, Matthias Stelljes, MD, Tao Wang, M. Luisa Paccagnella, Kevin Nguyen, Barbara Sleight, MD, Erik R. Vandendries, MD PhD, Alexander Neuhof, MD, A. Douglas Laird, PhD, Anjali S. Advani, MD

Blood (2019) 134 (Supplement_1): 1344.

DOI: https://doi.org/10.1182/blood-2019-122097

Published: 2019

Journal Articles

Safety and Efficacy of Allogeneic Stem Cell Transplantation after PD-1 Blockade for Patients with Relapsed/Refractory Classical Hodgkin Lymphoma

Anastasiya V Beynarovich, MD, Kirill Lepik, Nataliia Mikhailova, Elena Kondakova, Yuri Zalaylov, Evgeniya Borzenkova, Elena Babenko, Elena I Darskaya, MD PhD, Ivan S Moiseev, MD PhD, Axel Zander, Boris Afanasyev

Blood (2019) 134 (Supplement_1): 1561.

DOI: https://doi.org/10.1182/blood-2019-129076

Published: 2019

Journal Articles

A Phase 2 Trial of Inotuzumab Ozogamicin (InO) in Children and Young Adults with Relapsed or Refractory (R/R) CD22+ B-Acute Lymphoblastic Leukemia (B-ALL): Results from Children's Oncology Group Protocol AALL1621

Maureen M O'Brien, MD, Lingyun Ji, PhD, Nirali N. Shah, MD, Susan R. Rheingold, MD, Deepa Bhojwani, MD, Joanna S. Yi, MD, Constance M. Yuan, MD PhD, Andrew C Harris, MD, Patrick A. Brown, MD, Michael J. Borowitz, MD PhD, Olga Militano, PharmD, Meenakshi Devidas, PhD, Elizabeth A. Raetz, MD, Lia Gore, MD, Mignon L. Loh, MD

Blood (2019) 134 (Supplement_1): 741.

DOI: https://doi.org/10.1182/blood-2019-128977

Published: 2019

Journal Articles

A Multi-Center, Multinational, Prospective Observational Registry Study of Defibrotide in Patients Diagnosed with Severe Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) after Hematopoietic Cell Transplantation (HCT)

Mohamad Mohty, MD PhD, Marta Lisa Battista, Didier Blaise, MD PhD, Elisabetta Calore, MD, Simone Cesaro, Adam Gassas, Natalia Maximova, Katia Perruccio, Cecile Renard, MD, Robert Wynn, Marco Zecca, Myriam Labopin, MD, Raj Hanvesakul, Robert J. Ryan, MS, Fabio Ciceri, MD, Sarah Lawson, MD

Blood (2019) 134 (Supplement_1): 1972.

DOI: https://doi.org/10.1182/blood-2019-123529

Published: 2019

Journal Articles

Morbidity, Mortality, and Healthcare Utilization in a National Cohort of Pediatric Patients with Hemophagocytic Lymphohistiocytosis Who Received Hematopoietic Stem Cell Transplant

Archana Ramgopal, DO, Meghan McCormick, MD, Ram Kalpatthi, MD, Louis Rapkin, MD, James Zullo, Steven William Allen, MD BS

Blood (2019) 134 (Supplement_1): 2183.

DOI: https://doi.org/10.1182/blood-2019-132084

Published: 2019

Journal Articles

Exploring the Drivers of Potential Clinical Benefit in Initial Patients Treated in the Hgb-206 Study of Lentiglobin for Sickle Cell Disease (SCD) Gene Therapy

Mark C. Walters, MD, John F. Tisdale, MD, Janet L. Kwiatkowski, MD MSCE, Lakshmanan Krishnamurti, MD, Markus Y. Mapara, MD PhD, Manfred Schmidt, PhD, Alexandra L. Miller, Francis J. Pierciey, Jr., Wenmei Huang, PhD MS, Jean-Antoine Ribeil, MD PhD, Julie Kanter, MD, Alexis A. Thompson, MD MPH

Blood (2019) 134 (Supplement_1): 2061.

DOI: https://doi.org/10.1182/blood-2019-128814

Published: 2019

Journal Articles

Defibrotide Inhibits Endothelial Cell Injury Induced By Plasmas of Patients with Thrombotic Microangiopathies

Jeffrey Laurence, MD, Sonia Elhadad, PhD

Blood (2019) 134 (Supplement_1): 3676.

DOI: https://doi.org/10.1182/blood-2019-124158

Published: 2019

Journal Articles

Northstar-2: Updated Safety and Efficacy Analysis of Lentiglobin Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia and Non-β0/β0 Genotypes

Alexis A. Thompson, MD MPH, Mark C. Walters, MD, Janet L. Kwiatkowski, MD MSCE, Suradej Hongeng, MD, John B. Porter, MA MDFRCP FRCPath, Martin G. Sauer, MD, Adrian J. Thrasher, MBBS, PhD FMedSci, Isabelle Thuret, MD, Heidi Elliot, Ge Tao, PhD, Richard A. Colvin, MD PhD, Franco Locatelli, MD PhD

Blood (2019) 134 (Supplement_1): 3543.

DOI: https://doi.org/10.1182/blood-2019-126046

Published: 2019

Journal Articles

Treosulfan Metabolite (S, S-EBDM) Pharmacokinetics Influences Regimen Related Toxicity in Patients with Beta Thalassaemia Major Undergoing HSCT

Aswin Anand PAI, MSc, John C Panetta, PhD, Ezhil Pavai Mohanan, PhD, Raveen Stephen Stallon Illangeswaran, MSc, Balaji Balakrishnan, PhD, Eunice Sindhuvi Edison, PhD, Kavitha M Lakshmi, MSc, Uday Prakash Kulkarni, MD DM, Anup Joseph Devasia, MD DM, Fouzia N., Anu Korula, MD DM, Aby Abraham, MD DM, Biju George, MDDM, Vikram Mathews, MD DM, Alok Srivastava, MD,FRACP,FRCPA, Poonkuzhali Balasubramanian, PhD

Blood (2019) 134 (Supplement_1): 1977.

DOI: https://doi.org/10.1182/blood-2019-125604

Published: 2019

Journal Articles

A Meta-Analysis Evaluating the Risk of Bleeding-Related Adverse Events with Defibrotide Treatment

William Tappe, Saurabh Aggarwal, Ozlem Topaloglu, Massimo Iacobelli

Blood (2019) 134 (Supplement_1): 2016.

DOI: https://doi.org/10.1182/blood-2019-123686

Published: 2019

Journal Articles

Early Hyperbilirubinemia Is an Independent Predictor of Outcome after Allogeneic Stem Cell Transplantation and Correlates with Markers of Endothelial Cell Dysfunction

Thomas Luft, MD PhD, Hao Dai, Aleksandar Radujkovic, MD, David Schult, Joshua Majer-Lauterbach, Olga Blau, MD PhD, Lars Bullinger, Sihe Jiang, Carsten Müller-Tidow, MD, Peter Dreger, Olaf Penack, MD

Blood (2019) 134 (Supplement_1): 4487.

DOI: https://doi.org/10.1182/blood-2019-124284

Published: 2019

Journal Articles

Incidence, Risk Factors and Outcomes of Veno-Occlusive Disease / Sinusoidal Obstruction Syndrome (VOD/SOS) in Children with Severe Thalassemia (ST) Conditioned with Busulfan- Cyclophosphamide (Bu-Cy) Based Regimen

Stalin Ramprakash, MD MBBS, Rajat Kumar Agarwal, BS, C P Raghuram, MD, Pallavi Mehta, Deepa Trivedi, MD, Priya Marwah, Rajpreet Soni, Rakesh Dhanya, BE, Lawrence Faulkner, MD

Blood (2019) 134 (Supplement_1): 4499.

DOI: https://doi.org/10.1182/blood-2019-130841

Published: 2019

Journal Articles

Veno-Occlusive Disease (VOD) after Hematopoietic Stem Cell Transplant (HSCR): Always a Catastrophic Illness?

Paolo Bernasconi, MD, Anna Amelia Colombo, MD, Daniela Caldera, MD, Oscar Borsani, MD

Blood (2019) 134 (Supplement_1): 5649.

DOI: https://doi.org/10.1182/blood-2019-125608

Published: 2019

Journal Articles

An Update of Australasian Trends in Allogeneic Stem Cell Transplantation for Myelofibrosis in the Molecular Era

Blood (2019) 134 (Supplement_1): 5719.

DOI: https://doi.org/10.1182/blood-2019-126547

Published: 2019

Journal Articles

Radiation-Free Protocol for Patients with Acute Lymphoblastic Leukemia and Mixed Phenotype Acute Leukemia Undergoing Induction Chemotherapy and Allogeneic Hematopoietic Cell Transplantation - a Multicenter Historical Prospective Study

Odelia Amit, MD, Yael Bar-On, MD, Irit Avivi, Tsila Zuckerman, MD, Galit Perets, MD, Israel Henig, MD, Itai Levi, MD, Dana Yehudai-Ofir, MD, Shimrit Ringelstein Harlev, MD, Ron Ram, MD

Blood (2019) 134 (Supplement_1): 5654.

DOI: https://doi.org/10.1182/blood-2019-128248

Published: 2019

Journal Articles

Post-Transplant Cyclophosphamide for Gvhd Prophylaxis in Matched Unrelated Donor Transplantation Compared to ATG-Based Prophylaxis

Rebeca Bailén, MD, Mi Kwon, MD, Maria Jesus Pascual-Cascon, Anna Torrent, Christelle M Ferra, Jaime Sanz, MD PhD, Alberto Doblas-Marquez, Olga Benítez, MD, Jose Luis Piñana Sanchez, Gillen Oarbeascoa, MD, Nieves Dorado, MD, Muñoz Cristina, Carolina Martínez-Laperche, Javier Anguita, MD PhD, Ismael Buño, PhD, José Luis Díez-Martín, MD PhD

Blood (2019) 134 (Supplement_1): 3285.

DOI: https://doi.org/10.1182/blood-2019-124849

Published: 2019

Journal Articles

Study Design of an Open-Label, Single-Arm, Multicenter, Phase 2 Study to Evaluate the Safety and Efficacy of Defibrotide in Adult Patients with Transplant-Associated Thrombotic Microangiopathy

Vincent T. Ho, Nino Keshelava, Suzanne Swann, William Tappe

Blood (2019) 134 (Supplement_1): 3257.

DOI: https://doi.org/10.1182/blood-2019-123520

Published: 2019

Journal Articles

A Phase 1b/2 Study of the CD123-Targeting Antibody-Drug Conjugate IMGN632 As Monotherapy or in Combination with Venetoclax and/or Azacitidine for Patients with CD123-Positive Acute Myeloid Leukemia

Naval G. Daver, MD, Harry P. Erba, MD PhD, Nikolaos Papadantonakis, MDPhDMSc, Daniel J. DeAngelo, MD, Eunice S. Wang, MD, Marina Y Konopleva, MD PhD, Callum M. Sloss, PhD, Jiuzhou Wang, PhD, Kara E. Malcolm, RN, Patrick A. Zweidler-McKay, MD PhD, Hagop M. Kantarjian, MD

Blood (2019) 134 (Supplement_1): 2601.

DOI: https://doi.org/10.1182/blood-2019-128501

Published: 2019

2 3 4 5

NARROW

Incidence and Cost of Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome with and without Multi-Organ Dysfunction: Analysis of the Premier Healthcare Database

Comparable Outcomes between Unrelated Donor (8/8 or 7/8 matched) and Haploidentical Donor for Allogeneic Stem Cell Transplantation in Adult Patients with Severe Aplastic Anemia

Efficacy and Safety Outcomes in the Phase 3 INO-Vate Trial By Baseline CD22 Positivity Assessed By Local Laboratories

Safety and Efficacy of Allogeneic Stem Cell Transplantation after PD-1 Blockade for Patients with Relapsed/Refractory Classical Hodgkin Lymphoma

A Phase 2 Trial of Inotuzumab Ozogamicin (InO) in Children and Young Adults with Relapsed or Refractory (R/R) CD22+ B-Acute Lymphoblastic Leukemia (B-ALL): Results from Children's Oncology Group Protocol AALL1621

A Multi-Center, Multinational, Prospective Observational Registry Study of Defibrotide in Patients Diagnosed with Severe Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) after Hematopoietic Cell Transplantation (HCT)

Morbidity, Mortality, and Healthcare Utilization in a National Cohort of Pediatric Patients with Hemophagocytic Lymphohistiocytosis Who Received Hematopoietic Stem Cell Transplant

Exploring the Drivers of Potential Clinical Benefit in Initial Patients Treated in the Hgb-206 Study of Lentiglobin for Sickle Cell Disease (SCD) Gene Therapy

Defibrotide Inhibits Endothelial Cell Injury Induced By Plasmas of Patients with Thrombotic Microangiopathies

Northstar-2: Updated Safety and Efficacy Analysis of Lentiglobin Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia and Non-β0/β0 Genotypes

Treosulfan Metabolite (S, S-EBDM) Pharmacokinetics Influences Regimen Related Toxicity in Patients with Beta Thalassaemia Major Undergoing HSCT

A Meta-Analysis Evaluating the Risk of Bleeding-Related Adverse Events with Defibrotide Treatment

Early Hyperbilirubinemia Is an Independent Predictor of Outcome after Allogeneic Stem Cell Transplantation and Correlates with Markers of Endothelial Cell Dysfunction

Incidence, Risk Factors and Outcomes of Veno-Occlusive Disease / Sinusoidal Obstruction Syndrome (VOD/SOS) in Children with Severe Thalassemia (ST) Conditioned with Busulfan- Cyclophosphamide (Bu-Cy) Based Regimen

Veno-Occlusive Disease (VOD) after Hematopoietic Stem Cell Transplant (HSCR): Always a Catastrophic Illness?

An Update of Australasian Trends in Allogeneic Stem Cell Transplantation for Myelofibrosis in the Molecular Era

Radiation-Free Protocol for Patients with Acute Lymphoblastic Leukemia and Mixed Phenotype Acute Leukemia Undergoing Induction Chemotherapy and Allogeneic Hematopoietic Cell Transplantation - a Multicenter Historical Prospective Study

Post-Transplant Cyclophosphamide for Gvhd Prophylaxis in Matched Unrelated Donor Transplantation Compared to ATG-Based Prophylaxis

Study Design of an Open-Label, Single-Arm, Multicenter, Phase 2 Study to Evaluate the Safety and Efficacy of Defibrotide in Adult Patients with Transplant-Associated Thrombotic Microangiopathy

A Phase 1b/2 Study of the CD123-Targeting Antibody-Drug Conjugate IMGN632 As Monotherapy or in Combination with Venetoclax and/or Azacitidine for Patients with CD123-Positive Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only